Galecto, Inc.
Galecto, Inc. (GLTO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GLTO · as of Jun 8, 2026
Key Statistics
Explore Galecto, Inc. Data
glto stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 60.0%
The GLTO analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $43.67, representing +102.36% upside from the current price of $21.58.
Competitors & Peers
glto competitorsGLTO
ACXP
ADIL
APRE
APVO
BCDAStock Performance
Full HistoryAbout Galecto, Inc.
Galecto, Inc. is a clinical-stage biotechnology company focused on creating new therapeutic agents for a range of illnesses, including fibrotic conditions, cancer, and inflammation. Its most advanced …
what is galecto, inc. · glto stock overview · galecto, inc. company profile · who is galecto, inc. ceo · glto NASDAQ · galecto, inc. headquarters · galecto, inc. business segments
About Stock Overview & Key Data
Galecto, Inc. (GLTO) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 29, 2020. As of the latest trading session, GLTO stock price is $21.58, with a market capitalization of $34.5M. The stock has returned +555.93% over the past 12 months and -6.21% year-to-date.
According to 5 Wall Street analysts, the consensus rating for Galecto, Inc. stock is Buy, with an average 12-month price target of $43.67. In fiscal year 2025, Galecto, Inc. reported revenue of — and net income of -$209.8M. For detailed data — including Galecto, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Galecto, Inc. (GLTO) stock price is $21.58. The stock is traded on NASDAQ under the ticker symbol GLTO. The 52-week range is $2.01 – $38.33.